glp-1 hims Inc Novo Nordisk Signs Deal with

Pharmacovigilance studies consistently show a signal of increased reporting of thyroid cancer in patients treated with GLP-1 RA

Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

doi: 10.1053/j.gastro.2013.02.007

This study highlights that: Delayed gastric emptying is clinically significant Standard fasting guidelines may be insufficient Gastric ultrasound is a valuable tool for risk stratification As GLP-1 use continues to expand, anesthesiologists must adapt their practices to ensure patient safety

Importantly, these associations persist after accounting for improvements in glycemic control and body weight, suggesting that the observed neuroprotective signal may not be solely attributable to better metabolic management